Targeted Therapy Drugs Market Report – Research, Industry Analysis Reports and Market Demands

Global Targeted Therapy Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Targeted Therapy Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Kinase Inhibitors
- 1.3.3 ADC
- 1.3.4 Others
1.4 Market Analysis by Administration Route
- 1.4.1 Overview: Global Targeted Therapy Drugs Consumption Value by Administration Route: 2021 Versus 2025 Versus 2032
- 1.4.2 Oral Drugs
- 1.4.3 Injectable Drugs
- 1.4.4 Others
1.5 Market Analysis by Molecular Properties
- 1.5.1 Overview: Global Targeted Therapy Drugs Consumption Value by Molecular Properties: 2021 Versus 2025 Versus 2032
- 1.5.2 Small Molecule Drugs
- 1.5.3 Antibody Drugs
- 1.5.4 Others
1.6 Market Analysis by Application
- 1.6.1 Overview: Global Targeted Therapy Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Cancer
- 1.6.3 Rare Diseases
- 1.6.4 Others
1.7 Global Targeted Therapy Drugs Market Size & Forecast
- 1.7.1 Global Targeted Therapy Drugs Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Targeted Therapy Drugs Sales Quantity (2021-2032)
- 1.7.3 Global Targeted Therapy Drugs Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: Targeted Therapy Drugs by Manufacturer

3.1 Global Targeted Therapy Drugs Sales Quantity by Manufacturer (2021-2026)
3.2 Global Targeted Therapy Drugs Revenue by Manufacturer (2021-2026)
3.3 Global Targeted Therapy Drugs Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Targeted Therapy Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Targeted Therapy Drugs Manufacturer Market Share in 2025
- 3.4.3 Top 6 Targeted Therapy Drugs Manufacturer Market Share in 2025
3.5 Targeted Therapy Drugs Market: Overall Company Footprint Analysis
- 3.5.1 Targeted Therapy Drugs Market: Region Footprint
- 3.5.2 Targeted Therapy Drugs Market: Company Product Type Footprint
- 3.5.3 Targeted Therapy Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Targeted Therapy Drugs Market Size by Region
- 4.1.1 Global Targeted Therapy Drugs Sales Quantity by Region (2021-2032)
- 4.1.2 Global Targeted Therapy Drugs Consumption Value by Region (2021-2032)
- 4.1.3 Global Targeted Therapy Drugs Average Price by Region (2021-2032)
4.2 North America Targeted Therapy Drugs Consumption Value (2021-2032)
4.3 Europe Targeted Therapy Drugs Consumption Value (2021-2032)
4.4 Asia-Pacific Targeted Therapy Drugs Consumption Value (2021-2032)
4.5 South America Targeted Therapy Drugs Consumption Value (2021-2032)
4.6 Middle East & Africa Targeted Therapy Drugs Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global Targeted Therapy Drugs Sales Quantity by Type (2021-2032)
5.2 Global Targeted Therapy Drugs Consumption Value by Type (2021-2032)
5.3 Global Targeted Therapy Drugs Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global Targeted Therapy Drugs Sales Quantity by Application (2021-2032)
6.2 Global Targeted Therapy Drugs Consumption Value by Application (2021-2032)
6.3 Global Targeted Therapy Drugs Average Price by Application (2021-2032)

7 North America

7.1 North America Targeted Therapy Drugs Sales Quantity by Type (2021-2032)
7.2 North America Targeted Therapy Drugs Sales Quantity by Application (2021-2032)
7.3 North America Targeted Therapy Drugs Market Size by Country
- 7.3.1 North America Targeted Therapy Drugs Sales Quantity by Country (2021-2032)
- 7.3.2 North America Targeted Therapy Drugs Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe Targeted Therapy Drugs Sales Quantity by Type (2021-2032)
8.2 Europe Targeted Therapy Drugs Sales Quantity by Application (2021-2032)
8.3 Europe Targeted Therapy Drugs Market Size by Country
- 8.3.1 Europe Targeted Therapy Drugs Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Targeted Therapy Drugs Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific Targeted Therapy Drugs Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Targeted Therapy Drugs Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Targeted Therapy Drugs Market Size by Region
- 9.3.1 Asia-Pacific Targeted Therapy Drugs Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Targeted Therapy Drugs Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America Targeted Therapy Drugs Sales Quantity by Type (2021-2032)
10.2 South America Targeted Therapy Drugs Sales Quantity by Application (2021-2032)
10.3 South America Targeted Therapy Drugs Market Size by Country
- 10.3.1 South America Targeted Therapy Drugs Sales Quantity by Country (2021-2032)
- 10.3.2 South America Targeted Therapy Drugs Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa Targeted Therapy Drugs Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Targeted Therapy Drugs Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Targeted Therapy Drugs Market Size by Country
- 11.3.1 Middle East & Africa Targeted Therapy Drugs Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Targeted Therapy Drugs Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 Targeted Therapy Drugs Market Drivers
12.2 Targeted Therapy Drugs Market Restraints
12.3 Targeted Therapy Drugs Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Targeted Therapy Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Targeted Therapy Drugs
13.3 Targeted Therapy Drugs Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Targeted Therapy Drugs Typical Distributors
14.3 Targeted Therapy Drugs Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Targeted Therapy Drugs market size was valued at US$ 161681 million in 2025 and is forecast to a readjusted size of US$ 231501 million by 2032 with a CAGR of 5.4% during review period.
In 2025, global Targeted Therapy Drugs reached approximately 73.33 M Units, with an average global market price of around 2143 USD per Unit.
Targeted therapy drugs are medicines designed to specifically act on defined molecular targets—such as genes, proteins, receptors, or signaling pathways—that play a key role in the development or progression of a disease. Unlike traditional therapies that act broadly on rapidly dividing cells or whole organ systems, targeted therapies aim to interfere precisely with disease-driving mechanisms, thereby improving therapeutic effectiveness while reducing unintended damage to healthy cells.Targeted therapies are widely used in oncology, where they block cancer-specific mutations, growth signals, or angiogenesis pathways, but they are also increasingly important in autoimmune diseases, inflammatory disorders, and rare genetic conditions. These drugs may take the form of small molecules (often taken orally and acting inside cells) or biologics such as monoclonal antibodies (typically acting on extracellular or cell-surface targets). Their development relies heavily on advances in molecular biology, genomics, and biomarker identification.
Targeted therapy drugs address some of the most persistent pain points in modern medicine by moving beyond broad, non-specific treatment approaches toward therapies that act on clearly defined molecular drivers of disease, enabling better efficacy with a more manageable safety profile and greater consistency in patient response. By aligning treatment with genetic mutations, signaling pathways, or disease-specific receptors, these drugs help reduce unnecessary toxicity, avoid overtreatment, and improve outcomes in conditions where traditional therapies often fall short or show high variability. The expansion of genomic testing, biomarker discovery, and molecular diagnostics has accelerated the adoption of targeted therapies, while rising prevalence of cancer, autoimmune disorders, and rare diseases continues to fuel demand for more precise and durable treatment options. Looking ahead, the market potential for targeted therapy drugs remains strong as pipelines deepen across oncology and non-oncology indications, combination strategies improve resistance management, and healthcare systems increasingly recognize the long-term value of therapies that deliver predictable, mechanism-based benefits, positioning targeted therapies as a cornerstone of future drug development and precision medicine.
The upstream raw materials for Targeted Therapy Drugs mainly include active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and excipients. Typical suppliers include Pfizer, Roche, Merck, and AstraZeneca, among others. Downstream applications are primarily in oncology and rare disease treatments.
The single-line production capacity of Targeted Therapy Drugs varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.
This report is a detailed and comprehensive analysis for global Targeted Therapy Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Targeted Therapy Drugs market size and forecasts, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2021-2032
Global Targeted Therapy Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2021-2032
Global Targeted Therapy Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2021-2032
Global Targeted Therapy Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (M Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Targeted Therapy Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Targeted Therapy Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Merck, Pfizer, AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Bayer, GSK, Daiichi Sankyo, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Targeted Therapy Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Kinase Inhibitors
ADC
Others
Market segment by Administration Route
Oral Drugs
Injectable Drugs
Others
Market segment by Molecular Properties
Small Molecule Drugs
Antibody Drugs
Others
Market segment by Application
Cancer
Rare Diseases
Others
Major players covered
Roche
Novartis
Merck
Pfizer
AstraZeneca
Johnson & Johnson
Bristol Myers Squibb
Bayer
GSK
Daiichi Sankyo
Amgen
Eli Lilly and Company
AbbVie
Sanofi
Takeda
Boehringer Ingelheim
Beigene, Ltd.
Jiangsu Hengrui Medicine
INNOVENT BIOLOGICS(SUZHOU)
Betta Pharmaceuticals
Remegen Co.,Ltd.
Shanghai Allist Pharmaceuticals
Innocare
Huiyu Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Targeted Therapy Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Targeted Therapy Drugs, with price, sales quantity, revenue, and global market share of Targeted Therapy Drugs from 2021 to 2026.
Chapter 3, the Targeted Therapy Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Targeted Therapy Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Targeted Therapy Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Targeted Therapy Drugs.
Chapter 14 and 15, to describe Targeted Therapy Drugs sales channel, distributors, customers, research findings and conclusion.

Buy now